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ABSTRACT
Objective: To evaluate the octapeptides related to human histatin 8 by in-silico and in-vitro studies.
Method: Schrodinger, LLC and Ellman’s method.
Results: The compound HH1 and HH2 was found to be potent docking score of −9.494 and −7.401 against acetylcholinesterase (AChE) enzyme. The 
IC50 value of HH1 and HH2 was found to be 0.39±0.28 and 0.78±0.15 µg/mL. However, these compounds are shown to be highly effective as compared 
with the control AChE inhibitor donepezil (0.065±0.0050 µg/mL). 
Conclusion: In-silico docking study was conducted for the designed octapeptides related to human histatin 8 against AChE enzyme shows significance 
binding affinity toward HH1 and HH2 peptides and the AChE inhibitory activity of octapeptides shown to be a highly potent inhibitor as compared 
with control donepezil.
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INTRODUCTION
Most of the drugs approved for AD treatment are acetylcholinesterase 
(AChE) inhibitors, which improve the AChE level in the brain by 
decreasing the hydrolysis of AChE. β amyloid (Aβ) formed by the 
continuously proteolytic processing of β-amyloid precursor protein 
by β-secretase and γ-secretase, plays a vital part in the pathogenesis 
of AD [1]. Recent evidence indicated certain links between Aβ and 
AChE [2]. Right now the development of single molecule may possess 
multiple concomitant biological properties and would have more 
advantages than combination therapy due to deficient of drugs which 
are monofunctional, defeat only a single target. Furthermore, the risk of 
drug-drug interactions can be reduced, and the therapeutic treatment 
has significantly simplified and better patient compliance [3]. Current 
scenario, peptides are the alternative of heterocyclic compounds in 
pharmaceutical industry. Short peptides are linear molecules having 
2-20 amino acids present in the sequence of the peptide. Right now 
more than 50 healing peptides are available in the market and some of 
the peptides are in clinical trials [4] (phase I-III). To overcome the risk 
factor of peptide delivery, balancing of hydrophobic and hydrophilic 
characters (amphiphile) [5]. Short and ultra-short peptides were 
inhibiting aggregation of Aβ and reduce its toxic effects. It is also shown 
to be effective in AD rodent animal models [6]. Based on the above 
factors, to evaluate the octapeptides related to human histatin 8 by 
in-silico and in-vitro method and correlate both. Synthetic part of the 




Acetylthiocholine iodide (ATCI), sodium phosphate buffer and AChE 
were purchased from SIGMA-ALDRICH. 5, 5-dithio-bis-(2-nitrobenzoic 
acid) (DTNB) from Thermo Fisher Scientific. Buffers and other 
chemicals were of analytical grade.
Instruments
Ultraviolet–visible spectroscopy spectrophotometer from SHIMADZU 
and incubator from Thermo Scientific.
Methods
Molecular docking studies with octapeptides
Initially, the octapeptides (HH1, HH2, and HH3) sequences de novo 
peptide structure was predicted using the PEP-FOLD server at mobile 
server portal [bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD/].
Before docking the X-ray crystal structures of acetyl cholinesterase (AChE) 
with pdb id: 1EVE were retrieved from the RCSB Protein Data Bank [8-10]. 
Their corresponding protein structures were subsequently prepared 
using the Protein Preparation Wizard in the Schrödinger software 
suite [11]. The respective AChE structure is optimized by removing the 
water molecules, heteroatoms, and cofactors. Hydrogen, missing atoms, 
bonds, and charges were computed. Further, all the three octapeptides 
were docked to AChE using guide peptide docking procedure [11].
Further, receptor grid was generated around the AChE enzyme active 
site by choosing centroid of AChE enzyme complexed ligand (aricept), 
with the grid box size set to 20 Å radius using receptor grid generation 
panel implemented in Glide [11].
The ligand structures (Fig. 1) were constructed using the splinter 
dictionary of Maestro 9.3 (Schrodinger, LLC) using the Optimized 
Potentials for Liquid Simulations-All Atom (OPLS-AA) force field with 
the steepest descent followed by curtailed Newton conjugate gradient 
protocol. Partial atomic charges were computed using the OPLS-AA 
force field.
All the octapeptides (HH1, HH2, and HH3) docking calculations were 
performed using standard precision peptide docking mode. The Glide 
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docking score was used to determine the best-docked structure from 
the output. The binding affinity of the AChE/octapeptides complexes 
was expressed as docking scores. The interactions of these docked 
complexes were further analyzed using PyMOL [12].
Anti-alzheimer’s activity
In-vitro AchE assay
The assay for measuring AChE activity was evaluated based on Ellman’s 
method [13,14]. The principle of this method is based on enzyme 
hydrolyzes the substrate ATCI into thiocholine and acetic acid. Then, 
thiocholine is allowed to react with DTNB, and formation of yellow 
color. The intensity of color formation proportional to the activity of 
the enzyme.
Briefly, 150 µl of 0.1 M sodium phosphate buffer (pH 8.0), 10 µl of 
the test compound, and 20 µl of the enzyme solution (0.1 units/mL) 
were added and incubated for 15 minutes at 25°C. After that followed 
by mixed with 10 µl of DTNB (10 mM) and 10 µl of ATCI (14 mM) to 
initiate the reaction, incubate for 10 minutes. The color formation was 
measured at 410 nm wavelength. The controls contained the solvent 
to dissolve the compound instead of test compound. The percentage 
inhibition for each test solution was then calculated using the following 
equation:
Inhibition (%) = (1- absorbance sample/absorbance control) × 100
RESULTS AND DISCUSSION
Docking with octapeptides on AchE
From docking analysis of all the three octapeptides, it was found that 
HH1 and HH2 dock to AChE with docking score of −9.494 and −7.401 
with the corresponding IC50: 0.39±0.28 and IC50: 0.78±0.15 µg/mL, 
while HH3 peptide did not dock as the peptide was not stable to bind 
Fig. 1: The ligand structures
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to the AChE active site. This result is also in accordance with HH3 
IC50: 86.45±0.32 value, showing declined anticholinesterase enzyme 
inhibition activity. The binding mode of the HH1 peptide to AChE 
structure shows that the amino terminal end residue Lys1 backbone 
NH form a hydrogen bond with side chain oxygen of Asn280. While 
the phe2 of HH1 forms a hydrophobic interaction with side chain of 
Tyr70. Following it HH1 peptide residue His3 side chain imidazole 
ring nitrogen forms a hydrogen bond with Gln74 side chain NH, while 
Glu4 of peptide did not show any key interaction. In the case of Lys6, its 
side chain aliphatic alkane part forms a hydrophobic interaction with 
Phe290, Phe331, and Tyr334. Interestingly, face-to-face π-π stacking 
between Phe330 and with imidazole ring of His6, while the His7 
imidazole NH forms a hydrogen bond with Tyr70 backbone oxygen. 
In addition, the peptide Ser8 backbone forms a hydrogen bond with 
Tyr130 side chain OH and finally the terminal OH forms a hydrogen 
bond with one of the side chain oxygen of Glu199 (Fig. 2a).
The binding mode of the HH2 peptide (gray stick) in the AChE active 
site, where the HH2 peptide residues Lys1 and Lys4 side chain’s one of 
the NH of NH3+ forms a hydrogen bond with Glu73 backbone oxygen 
and side chain oxygen of Asn280, respectively. While the Leu6 backbone 
NH forms a hydrogen bond with side chain OH of Tyr70. Meanwhile, the 
backbone oxygen and NH of Leu7 forms hydrogen bonds with Tyr121 
side chain OH. Finally, the carboxyl terminal residue Lys8’s side chain 
forms a hydrogen bond with backbone oxygen is 440 (Fig. 2b).
In-vitro AchE assay
The assay of AChE was based on an improved Ellman’s method in 
a 96 well plate reader using QuantiChrome assay kit (USA). One of 
the characteristic changes that occur in AD is an increase in AChE 
activity, the enzyme responsible for acetylcholine hydrolysis, from 
both cholinergic and non-cholinergic neurons of the brain. The results 
obtained from the octapeptides related to human histatin 8 against 
AChE enzyme inhibition activity and the percentage inhibition was 
evaluated and tabulated in Table 1. IC50 value of HH1 and HH2 was found 
to be 0.39±0.28 and 0.78±0.15 µg/mL. However, these compounds 
are shown to be highly effective as compared with the control AChE 
inhibitor donepezil (0.065±0.0050 µg/mL).
Statistical analysis
Data were presented as mean±standard deviation. All analyses were 
performed in triplicates. GraphPad Prism 5 and Microsoft Excel 2007 
were used for the statistical and graphical evaluations.
CONCLUSION
In-silico docking study was conducted for the designed octapeptides 
related to human histatin 8 against AChE enzyme shows significance 
binding affinity toward HH1 and HH2 peptides. The AChE inhibitory 
activity of octapeptides related to human histatin 8 was evaluated 
using Ellman’s method, and these compounds are shown to be a 
highly potent inhibitor as compared with control AChE inhibitor 
donepezil. In-silico results correlates with the in-vitro results. The 
result showed that HH1 and HH2 exhibited more capability to inhibit 
AChE enzyme.
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Table 1: IC50 value of octapeptides related to human histatin 8 
and control
S. No Compounds code IC50 (µg/mL)




Results were expressed as mean±SD (n=3), IC50 for donepezil control for AChE 
inhibition assay was 0.065±0.0050 µg/mL, AChE: Acetylcholinesterase
Fig. 2: Shows the binding mode (a) HH1 peptide (blue stick), 
(b) HH2 peptide (gray stick), in the acetyl cholinesterase active site. 
The key interacting residues are shown in magenta color lines, and 
the hydrogen bonds are represented as yellow dashed lines
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